Leerink Partnrs Has Negative Outlook of ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities researchers at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a report released on Sunday, November 9th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.86) per share for the year, down from their previous estimate of ($0.83). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q4 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at ($1.01) EPS and FY2029 earnings at ($1.10) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.10.

Several other equities research analysts have also recently commented on the company. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Eledon Pharmaceuticals in a research note on Tuesday, September 2nd. Craig Hallum started coverage on shares of Eledon Pharmaceuticals in a report on Friday, July 25th. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Eledon Pharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Eledon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Eledon Pharmaceuticals Stock Performance

Shares of Eledon Pharmaceuticals stock opened at $1.89 on Wednesday. The company has a market capitalization of $113.18 million, a P/E ratio of -1.62 and a beta of 0.63. Eledon Pharmaceuticals has a 1 year low of $1.43 and a 1 year high of $5.08. The company’s fifty day moving average is $2.96 and its two-hundred day moving average is $3.00.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Zimmer Partners LP boosted its position in shares of Eledon Pharmaceuticals by 0.7% in the first quarter. Zimmer Partners LP now owns 754,970 shares of the company’s stock worth $2,559,000 after buying an additional 4,970 shares during the period. CW Advisors LLC acquired a new position in Eledon Pharmaceuticals during the 1st quarter worth approximately $34,000. Ground Swell Capital LLC acquired a new position in Eledon Pharmaceuticals during the 2nd quarter worth approximately $31,000. ProShare Advisors LLC purchased a new position in Eledon Pharmaceuticals in the 2nd quarter worth approximately $33,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Eledon Pharmaceuticals in the first quarter valued at approximately $41,000. Institutional investors and hedge funds own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).